GSK is seeking to relaunch Blenrep after its market withdrawal in 2022. The pharma is eyeing a second-line niche for the antibody-drug conjugate in the treatment of relapsed or refractory multiple myeloma.
Tag Archive for: multiple myeloma
The companies leased interim results from the Phase III CARTITUDE-4 study, touting significant survival improvement in multiple myeloma patients after treatment with their CAR-T therapy Carvykti (ciltacabtagene autoleucel).
After a brief market exit in November 2022, GSK appears to be giving its multiple myeloma treatment Blenrep a second chance, with company executives touting its “multi-blockbuster” potential in a virtual oncology-focused investor event on Monday.
Sanofi announced on Monday at the ASCO annual meeting that a combination treatment that includes its anti-CD38 monoclonal antibody Sarclisa had shown a positive effect in reducing disease progression and death in multiple myeloma patients. The news comes as Sanofi pushes for another indication for the drug.
An FDA advisory committee agreed that using minimal residual disease could be a viable surrogate endpoint for accelerated approval for drug development in multiple myeloma.
Today the agency allowed the use of Bristol-Myers Squibb (BMY.N) and 2seventybio’s cell therapy Abecma in less severely affected patients with a type of blood cancer.
A study showed GSK’s experimental drug Blenrep helped extend survival in patients with a type of blood cancer without symptoms worsening, marking a potential comeback for the drug after several setbacks.
Johnson & Johnson’s anti-BCMA antibody can now be dosed once every two weeks in relapsed or refractory multiple myeloma patients who have achieved and maintained complete response for at least six months.
Yesterday the company posted findings from an interim analysis of the Phase III DREAMM-7 trial showing that its antibody-drug conjugate Blenrep, when used in a three-drug regimen, led to a significant improvement in progression-free survival in patients with relapsed or refractory multiple myeloma.
An FDA advisory committee will meet to review J&J and Legend Biotech’s supplemental BLA for Carvykti for the treatment of relapsed or refractory multiple myeloma patients who have undergone at least one prior line of therapy.